首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5510001篇
  免费   425222篇
  国内免费   18869篇
耳鼻咽喉   76332篇
儿科学   177659篇
妇产科学   146567篇
基础医学   814696篇
口腔科学   157042篇
临床医学   515551篇
内科学   1000374篇
皮肤病学   128119篇
神经病学   454212篇
特种医学   213269篇
外国民族医学   1115篇
外科学   822320篇
综合类   161471篇
现状与发展   24篇
一般理论   3219篇
预防医学   467739篇
眼科学   133218篇
药学   391588篇
  32篇
中国医学   15144篇
肿瘤学   274401篇
  2021年   59224篇
  2019年   61439篇
  2018年   80100篇
  2017年   60967篇
  2016年   67728篇
  2015年   79768篇
  2014年   115307篇
  2013年   182596篇
  2012年   164225篇
  2011年   176466篇
  2010年   140703篇
  2009年   137077篇
  2008年   159369篇
  2007年   172004篇
  2006年   178134篇
  2005年   172379篇
  2004年   171747篇
  2003年   159944篇
  2002年   147853篇
  2001年   215906篇
  2000年   213795篇
  1999年   190173篇
  1998年   79899篇
  1997年   73406篇
  1996年   71159篇
  1995年   66776篇
  1994年   60864篇
  1993年   56218篇
  1992年   142477篇
  1991年   138262篇
  1990年   133177篇
  1989年   129118篇
  1988年   119190篇
  1987年   117265篇
  1986年   111252篇
  1985年   108515篇
  1984年   87144篇
  1983年   76023篇
  1982年   55194篇
  1981年   50849篇
  1980年   47727篇
  1979年   77532篇
  1978年   59839篇
  1977年   52071篇
  1976年   48945篇
  1975年   49760篇
  1974年   57117篇
  1973年   55257篇
  1972年   51612篇
  1971年   47872篇
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
41.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome.  相似文献   
42.
43.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy  相似文献   
44.
45.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
46.
47.
48.
49.
50.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号